Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 7Oropharyngeal Neoplasms 7Carcinoma 6Lung Neoplasms 5Nasopharyngeal Carcinoma 4Mouth Neoplasms 4Laryngeal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Mesothelioma, Malignant 3Lymphoid Interstitial Pneumonia 3Hypopharyngeal Neoplasms 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Ganglioneuroblastoma 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Tongue Neoplasms 1Solitary Fibrous Tumor, Pleural 1Sinonasal Squamous Cell Carcinoma 1Salivary Gland Neoplasms 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Medulloblastoma 1Locally Advanced Cervical Adenocarcinoma 1Liver Neoplasms 1

Interventions

pembrolizumab 10Specimen Handling 9Magnetic Resonance Spectroscopy 8enfortumab vedotin 7Nivolumab 7Ipilimumab 4Gemcitabine 4sacituzumab govitecan 3Docetaxel 3Cisplatin 3CTLA-4 Antigen 3cabozantinib 2atezolizumab 2Taxes 2Paclitaxel 2Mitomycin 2Immunoglobulin G 2Disulfides 2Carboplatin 2tislelizumab 1temsirolimus 1tazemetostat 1sapanisertib 1relatlimab 1lenvatinib 1eribulin 1erdafitinib 1durvalumab 1belinostat 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × 1,2-diaminocyclohexaneplatinum II citrate × 30 days × Clear all
NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
320 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡